Henry Schein's results for Q3 2026 (quarter ended Sep 26, 2026) come from the company's own earnings release, filed with the SEC on 2026-11-03. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $3,471 million (+4.0% vs a year earlier) |
| Diluted EPS (GAAP) | $1.06 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $1.56 |
| Full-year guidance | Raised |
Guidance
Henry Schein raised 2026 non-GAAP EPS guidance to $5.50–5.56 from $5.29–5.39 and kept 4.5–5.5% sales growth.
Why this label: Release 'raised its financial guidance': non-GAAP EPS $5.50-5.56 (from $5.29-5.39), adj EBITDA growth to high-single digits; sales growth unchanged.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| non-GAAP diluted EPS | FY2026 | $5.50–5.56 | $5.29–5.39 |
| total sales growth | FY2026 | 4.5%–5.5% | 4.5%–5.5% |
| adjusted EBITDA growth | FY2026 | high-single-digits | mid to high-single-digits |
From the release
Revenue: "Net sales $ 3,471 $ 3,339 $ 10,297 $ 9,747"
Earnings per share: "Q3 2026 GAAP diluted EPS of $1.06, up 26.2% versus prior year; Q3 2026 non-GAAP diluted EPS of $1.56, up 13.0% versus prior year"
non-GAAP diluted EPS: "2026 non-GAAP diluted EPS 3 $5.50 to $5.56 $5.29 to $5.39"
total sales growth: "2026 total sales growth 4.5% to 5.5% 4.5% to 5.5%"
adjusted EBITDA growth: "Raises FY2026 guidance for non-GAAP diluted EPS (A) to $5.50 to $5.56 and Adjusted EBITDA growth to high-single-digits"
Key fact: Raised 2026 non-GAAP EPS guidance to $5.50–$5.56; U.S. dental merchandise sales up 8.6%
Source
Henry Schein earnings release (SEC filing), accession 0001000228-26-000059, filed 2026-11-03.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.